Pilot trial of Melissa officinalis L. leaf extract in the treatment of volunteers suffering from mild-to-moderate anxiety disorders and sleep disturbances

Abstract

Botanicals are an alternative option to prescription drugs for the alleviation of symptoms due to anxiety disorders and insomnia. Melissa officinalis L. has been shown as an anti-stress and anxiolytic agent. We previously reported moderate stress improvement in mice in which Cyracos(®), a standardized Melissa officinalis L. extract, was administrated. Cyracos(®) contains phytochemicals that inhibit gamma-aminobutyric acid catabolism. This was a prospective, open-label, 15-day study to evaluate the efficacy of Cyracos(®) on stressed volunteers, who have mild-to-moderate anxiety disorders and sleep disturbances. Using clinician rating criteria, primary outcomes showed improvement of symptoms. Cyracos(®) reduced anxiety manifestations by 18% (p < 0.01), ameliorated anxiety-associated symptoms by 15% (p < 0.01) and lowered insomnia by 42% (p < 0.01). As much as 95% of subjects (19/20) responded to treatment, of which 70% (14/20) achieved full remission for anxiety, 85% (17/20) for insomnia, and 70% (14/20) for both. Our study demonstrates, for the first time that chronic administration of Melissa officinalis L. relieves stress-related effects. It is critical that further studies incorporate a placebo and investigate physiological stress markers.

Fig. 1

Anxiety manifestations before and after 15 days of treatment with 600 mg Cyracos^® (300 mg twice a day) in 20 volunteers affected by anxiety disorders and sleep disturbances. *p < 0.05; **p < 0.01

Fig. 2

Anxiety-associated symptoms before and after 15 days of treatment with 600 mg Cyracos^® (300 mg twice a day) in 20 volunteers affected by anxiety disorders and sleep disturbances. *p < 0.05; **p < 0.01

Fig. 3

Insomnia parameters before and after 15 days of treatment with 600 mg Cyracos^® (300 mg twice a day) in 20 volunteers affected by anxiety disorders and sleep disturbances. **p < 0.01